Adcendo and Multitude ink ADC deal potentially worth $1bn
Adcendo will acquire ex-China global rights for Multitude’s tissue factor-targeting ADC.
Themes
Phanes acquires second FDA orphan designation for bispecific antibody
How clinical trials can use AI responsibly and effectively
Era of ADCs: Pharma companies innovate to stand out in a buzzing market
BioNTech exits PD-L1 development with Genmab as Q2 revenues drop
Rejuvenate and SAS partner to harness AI for age-related diseases
MHRA approves Pfizer-BioNTech’s Comirnaty JN.1 vaccine
The potential of 3D printing in drug development and delivery
